Occlusion Devices Market is Segmented By Product (Occlusion Removal Devices, Embolization Devices, Support Devices), By Application (Neurology, Peripheral Vascular Disease, Oncology, Urology, Other), By End-User (Hospitals, Ambulatory Surgical Centers, Other), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030
Occlusion Devices Market Overview
The Global Occlusion Devices Market size was valued at a CAGR of 5.4 % during the forecast period (2023-2030). Occlusion devices create occlusions in vessels to stop or remove the occlusion. In treating strokes caused by atrial fibrillation, these medical devices have proven more effective than anticoagulation therapy. The factors influencing the growth of the occlusion devices market are the increasing technological developments and rising adoption of minimally invasive surgeries.
Occlusion Devices Market Summary and Scope
|
Metrics |
Details |
|
Market CAGR |
5.4% |
|
Segments Covered |
By Product, By Application, By End-User, By Application, and By Region |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
|
Fastest Growing Region |
Asia Pacific |
|
Largest Market Share |
North America |
To Get a Free Sample Click Here
Occlusion Devices Market Dynamics and Trends
The increasing technological developments are expected to drive the market growth in the forecast period
Transcatheter closure is widely regarded as a highly effective method of treating abnormal blood flows and thrombus embolization in the heart. It allows for the closure of four different congenital heart defects (CHDs) and stroke-associated left atrial appendage closure (LAA). Advances in occlusion device materials and configurations have accelerated the shift from open-heart surgery with high complexity and morbidity, or lifelong medication with a high risk of bleeding, to minimally invasive deployment. Over the last decades, a wide range of occlusion devices has been developed, particularly novel ones such as biodegradable and 3D-printed occlusion devices, regarded as next-generation alternatives to conventional Nitinol-based occlusion devices biodegradability, customization, and improved biocompatibility.
Occlusion device implantation has become a widely accepted and highly effective treatment for obstructing abnormal blood/thrombus flow within the heart. Because conventional Nitinol-based occluders have serious complications such as erosion and displacement, next-generation occluders with reduced complications and improved biocompatibility have emerged. Occlusion material has been subjected to the most significant changes due to technological advancement. Some materials, such as detachable balloons, have been rendered obsolete due to the risk of deflation and migration into distal vascular territories. Nowadays, better alternatives exist, and conventional balloon catheters are only used for temporary occlusions, such as blocking an artery during active bleeding or in conjunction with other embolization material to avoid migration or to achieve blood stasis and improve the agent's effect. Another aspect of technological advancement is an increase in safety. Hence, all these technological developments are expected to drive market growth in the forecast period.
Limitations associated with occlusion devices are expected to hamper the market growth
Although the GGVOD (Grifka-Gianturco vascular occlusion device) the sack and vessel diameters are equal during several successful implantations, this could theoretically result in incomplete vessel occlusion or device embolization. Because veins are more compliant than arteries, venous structures may require a larger sack diameter. Furthermore, large vessels (7 to 9 mm) may necessitate a more than 1.0 to 1.5 mm larger sack to provide adequate transmural pressure. The optimal diameter of the sack in relation to the vessel diameter is still being researched. A short vessel is required to safely implant the GGVOD. A vessel length at least twice the sack diameter was used in this study (e.g., a 5-mm-diameter sack implanted in a 10-mm-long vessel). is inserted through an 8F sheath. If an arterial approach is required, the GGVOD's use in small infants may be limited by this sheath size. To implant the GGVOD, a long delivery sheath must be positioned in the desired vessel, as with all occlusion devices. If the vessel follows a tortuous path or has an acute-angle bend, sheath placement may be difficult (which occurs in some modified Blalock-Taussig shunts). An improved sheath is used to mitigate this issue. This sheath is made of high-quality blue Teflon (Cook Inc), which is kink-resistant and can be curved manually in a hot water bath. The sack must maintain adequate transmural pressure on the vessel. Hence, due to all these limitations, the market is expected to be hampered in the forecast period.
COVID-19 Impact Analysis on Occlusion Devices Market
The coronavirus disease pandemic of 2019 is wreaking havoc on healthcare systems worldwide. Waiting lists for non-urgent structural heart (SH) interventions continue to grow several months after the COVID-19 outbreak. Limitations in ICU beds and anesthesiology represent a significant barrier to performing non-urgent SH interventions and are a valid reason to shift to less invasive approaches. The left atrial appendage occlusion (LAAO) perfectly reflects this difficult situation. The COVID-19 pandemic had a direct impact on left atrial appendage occlusion procedures. Less invasive strategies would allow for a more consistent workflow for this indication. During the coronavirus pandemic, the growth rate of the LAA closure devices industry is expected to have grown. The governments of various countries are taking initiatives to raise public awareness about the importance of left atrial appendage closure devices during the pandemic, which is expected to drive market growth in the forecast period. Furthermore, several manufacturers are focusing on product improvements to gain a strong position and maintain their position in the global market during the coronavirus emergency.
Occlusion Devices Market Segment Analysis
Based on application, the Neurology segment is expected to dominate the market growth
Artery occlusion and bypass surgery is a two-step procedure that combines open microsurgery with endovascular coiling. This procedure aims to coil the entire diseased portion of the blood vessel and then bypass the blood flow to the affected area of the brain. The difference between this and endovascular coiling is that this procedure closes (occludes) the entire vessel rather than just placing coils in the aneurysm sac. The rising prevalence of brain aneurysms and the introduction of new technologically advanced products are expected to drive the market's overall growth.
According to the Brain Aneurysm Foundation's 2020 estimates, 6.5 million people in the United States have an unruptured brain aneurysm. Furthermore, approximately 30,000 people in the United States are affected by a ruptured brain aneurysm each year. Women, particularly those over 55, are more likely than men to have a brain aneurysm rupture. This risk is expected to rise as the geriatric population grows in the coming years. According to a United Nations report from 2017, the global population aged 60 and up is expected to grow from 12.7 percent in 2017 to 21.3 percent by 2050. Hence, the growing prevalence of aneurysms is expected to drive the market growth of this segment.
Occlusion Devices Market Geographical Share
North America region is expected to hold the largest market share in the global occlusion devices market
The growing use of minimally invasive surgeries and improved healthcare infrastructure Furthermore, the increasing approval of new occlusion devices and the presence of key players in this region is expected to boost the market's overall growth. For instance, Abbott Laboratories is a multinational American medical device and health care company headquartered in the United States. On August 16th, 2021, the U.S FDA approved the company's Amplatzer Amulet Left Atrial Appendage Occluder intended to treat people with atrial fibrillation (AFib) who are at risk of having an ischemic stroke. The device provides immediate closure of the left atrial appendage (LAA). In this area, blood clots can form in people with AFib, lowering the risk of stroke and removing the need for blood-thinning medication.
Occlusion Devices Companies and Competitive Landscape
The global occlusion devices market is moderately competitive with mergers, acquisitions, and product launches. Some of the key players in the market are Abbott Laboratories, Boston Scientific Corporation, Lepu Medical Technology, Edwards Lifesciences Corporation, W. L. Gore & Associates, Inc., Medtronic plc, Merit Medical Systems, Penumbra, Inc, and Terumo Corporation.
Boston Scientific Corporation
Overview: Boston Scientific is a medical device company based in Massachusetts specializing in the non-invasive treatment of cardiovascular, respiratory, neurological, digestive, urological, and pelvic conditions. The company was founded in 1979.
Product Portfolio: TruePath Chronic Total Occlusion Device (CTO) is a powerful new intraluminal treatment option for chronic total occlusions. The guidewire-like profile is nearly half the size of competitive offerings, measuring 0.018"/0.46 mm in diameter and designed for optimal steering and crossing. The self-rotating tip works smoothly once it is in place.
Key Development: On July 22nd, 2020, The next generation Watchman FLX Left Atrial Appendage Closure (LAAC) Device from Boston Scientific was approved by the US FDA. The Watchman FLX is designed to lower the risk of stroke in patients with non-valvular atrial fibrillation (NVAF) who require an alternative to oral anticoagulation therapy by permanently closing off the left atrial appendage – the area of the heart where stroke-causing blood clots commonly form in NVAF.
